|
Dupilumab Clinical Trials
10 actively recruiting trials across 6 locations
▼ -1 trial since May 2026
Also known as: DUPIXENT, Dupixent, Dupixent®, REGN668, SAR231893
Pipeline
Early 1: 1Phase 2: 1Phase 3: 1Phase 4: 3Phase 1/2: 1
Top Sponsors
- Sanofi4
- University of California, San Diego1
- The University of Texas Health Science Center at San Antonio1
- Sally E. Wenzel MD1
- Rima Patel1
Other3 trials
New York, New York2 trials
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Icahn School of Medicine at Mount Sinai
Phase 1/2
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
Mount Sinai Health System
Early 1
Birmingham, Alabama1 trial
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
University of Alabama at Birmingham - School of Medicine- Site Number : 8400003
Phase 4
Phoenix, Arizona1 trial
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
Phoenix Children's Hospital- Site Number : 8400001
Phase 3
Scottsdale, Arizona1 trial
Pittsburgh, Pennsylvania1 trial
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
The University of Pittsburgh Asthma Institute at UPMC
Phase 4
San Antonio, Texas1 trial
Dupilumab Effects Against Aeroallergen Challenge
Biogenics Research Chamber
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.